These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38443633)

  • 21. Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects.
    Brimhall DB; Petri N; D'Angelo P
    Clin Ther; 2018 May; 40(5):741-751. PubMed ID: 29699852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.
    Heise T; Nosek L; Dellweg S; Zijlstra E; Præstmark KA; Kildegaard J; Nielsen G; Sparre T
    Diabetes Obes Metab; 2014 Oct; 16(10):971-6. PubMed ID: 24720741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
    Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
    Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injection pain and postinjection pain of the anterior middle superior alveolar injection administered with the Wand or conventional syringe.
    Nusstein J; Lee S; Reader A; Beck M; Weaver J
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Jul; 98(1):124-31. PubMed ID: 15243483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.
    Anderson G; Meyer D; Herrman CE; Sheppard C; Murray R; Fox EJ; Mathena J; Conner J; Buck PO
    J Neurol; 2010 Nov; 257(11):1917-23. PubMed ID: 20953791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Injection site reactions after subcutaneous oligonucleotide therapy.
    van Meer L; Moerland M; Gallagher J; van Doorn MB; Prens EP; Cohen AF; Rissmann R; Burggraaf J
    Br J Clin Pharmacol; 2016 Aug; 82(2):340-51. PubMed ID: 27061947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study.
    Krop J; Kramer WG
    Clin Ther; 2017 Dec; 39(12):2345-2354. PubMed ID: 29191450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging of large volume subcutaneous deposition using MRI: exploratory clinical study results.
    Pettis RJ; Woodley WD; Ossege KC; Blum A; Bolick NG; Rini CJ
    Drug Deliv Transl Res; 2023 Sep; 13(9):2353-2366. PubMed ID: 36913105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design.
    Mathias N; Huille S; Picci M; Mahoney RP; Pettis RJ; Case B; Helk B; Kang D; Shah R; Ma J; Bhattacharya D; Krishnamachari Y; Doucet D; Maksimovikj N; Babaee S; Garidel P; Esfandiary R; Gandhi R
    Adv Drug Deliv Rev; 2024 Jun; 209():115301. PubMed ID: 38570141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Injection Speed, Volume, and Site on Pain Sensation.
    Zijlstra E; Jahnke J; Fischer A; Kapitza C; Forst T
    J Diabetes Sci Technol; 2018 Jan; 12(1):163-168. PubMed ID: 28990437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
    Beglinger C; Hu K; Wang Y; Bouillaud E; Darstein C; Wang Y; Mohideen P
    Endocrine; 2012 Oct; 42(2):366-74. PubMed ID: 22527887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain assessment of subcutaneous injections.
    Jørgensen JT; Rømsing J; Rasmussen M; Møller-Sonnergaard J; Vang L; Musaeus L
    Ann Pharmacother; 1996; 30(7-8):729-32. PubMed ID: 8826549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.
    Kokolakis G; Kreis G; Falqués M; Aparici M; Sondermann W
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2135-2144. PubMed ID: 35984626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous Injection Site Pain of Formulation Matrices.
    Shi GH; Pisupati K; Parker JG; Corvari VJ; Payne CD; Xu W; Collins DS; De Felippis MR
    Pharm Res; 2021 May; 38(5):779-793. PubMed ID: 33942212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study.
    Jen J; LaBadie RR; Liang Y; Crownover PH; Gao X; Hey-Hadavi JH
    Growth Horm IGF Res; 2013 Aug; 23(4):114-9. PubMed ID: 23651793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
.
    Jain M; Doughty D; Clawson C; Li X; White N; Agoram B; van der Merwe R
    Int J Clin Pharmacol Ther; 2017 Jul; 55(7):606-620. PubMed ID: 28590244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
    Chabra S; Gill BJ; Gallo G; Zhu D; Pitou C; Payne CD; Accioly A; Puig L
    Adv Ther; 2022 Jun; 39(6):2862-2872. PubMed ID: 35449322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of hypodermic needle dimensions on subcutaneous injection delivery--a pig study of injection deposition evaluated by CT scanning, histology, and backflow.
    Juul KA; Bengtsson H; Eyving B; Kildegaard J; Lav S; Poulsen M; Serup J; Stallknecht B
    Skin Res Technol; 2012 Nov; 18(4):447-55. PubMed ID: 22233448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.